StephenJSchusterMD

Hematology • Philadelphia, PA

Hematologic Oncology

Professor of Medicine, University of Pennsylvania

Join to view full profile

Dr. Schuster is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schuster's full profile

Already have an account?

Office
3400 Civic Center Blvd
Perelman Center for Advanced Medicine, 12th Floor
Philadelphia, PA 19104
Phone+1 215-662-3914

Summary

Dr. Stephen Schuster is a hematologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 36 years. He specializes in hematologic oncology and is experienced in hematologic oncology and leukemia. He has more than 100 publications and over 500 citings.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1988 - 1988
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1984 - 1988
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1981 - 1984
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1981

Certifications & Licensure

FL State Medical License 2024 - Present
PA State Medical License 1982 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Philadelphia Magazine Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Start of enrollment: 2000 Jan 01
Unknown status
Phase 3
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant Start of enrollment: 2007 Feb 01
Completed
Phase 1
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Start of enrollment: 2008 Jul 01
Completed
Phase 2
Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT) Start of enrollment: 2009 May 01
Completed
Not Applicable
CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2009 Mar 01
Completed
Phase 1
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas Start of enrollment: 2014 Feb 05
Completed
Phase 2
Retreatment With CTL019/CTL119 Start of enrollment: 2024 May 01
Not yet recruiting
Phase 1
CAR-T Followed by Bispecific Antibodies Start of enrollment: 2021 Nov 05
Recruiting
Phase 2
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

49 citations
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James Signorovitch
Blood Advances. 2020-04-14
2662 citations
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott
The New England Journal of Medicine. 2015-01-21
25 citations
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, Raymone Pajarillo, Christopher Tor Sauter
Cancer Discovery. 2022-10-05

Journal Articles

LRPAP1 Is a Frequent Proliferation-Inducing Antigen of BCRs of Mantle Cell Lymphomas and Can Be Used for Specific Therapeutic Targeting
Stephen J Schuster, Mariusz Wasik, Nature
Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States
Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma
Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
Stephen J Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Stephen J Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
Stephen J Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Stephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
Stephen J Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-cell TherapyDecember 2022

Press Mentions

Around the Nation: FDA Grants Expanded Approval for CAR-T TherapyJune 2nd, 2022
$FDA Approves Novartis Kymriah® CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular Lymphoma$
FDA Approves Novartis Kymriah® CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular LymphomaMay 28th, 2022
Where Does CAR T-cell Cancer Therapy Stand After Its FDA Approval?August 4th, 2021
Join now to see all